Table 1:
Demographic, clinical, imaging, and pathology data
| Patient characteristics (n=57) | |
|---|---|
| Age (years) | |
| Mean (SD) | 61.7 (7.0) |
| PSA (ng/ml) | |
| Median (Interquartile range (Q1–Q3)) | 15.0 (7.4–27.6) |
| NCCN Risk Stratification | |
| Intermediate-unfavorable risk | 4 (7.0) |
| High risk | 35 (61.4) |
| Very high risk | 18 (31.6) |
| Post-operative Grade Group* n (%) | |
| 2 (Gleason score 3+4) | 9 (15.0) |
| 3 (Gleason score 4+3) | 11 (18.3) |
| 4 (Gleason score 4+4, 3+5, 5+3) | 1 (1.7) |
| 5 (Gleason scores 4+5, 5+4,5+5) | 35 (58.3) |
| Total number of excised lymph nodes | 2480 |
| Median per patient (Interquartile range (Q1–Q3)) | 40.0 (33.5–51.5) |
| [18F]fluciclovine PET/CT positivity rate (N1 ± M1) n (%) | 21 (36.8) |
| Positivity rate per risk group: | |
| Intermediate-unfavorable risk (n=4) | 2 (50.0) |
| High risk (n=35) | 12 (34.3) |
| Very high risk (n=18) | 7 (38.9) |
| Metastatic disease based on truth (N1 ± M1) n (%) | 31 (54.4) |
| Metastatic disease per risk group: | |
| Intermediate-unfavorable risk (n=4) | 2 (50.0) |
| High risk (n=35) | 17 (48.6) |
| Very high risk (n=18) | 12 (66.7) |
*
n=56 patients that had radical prostatectomy